In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. - Test2 - elhamkhani - TriplyDB

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

http://www.wikidata.org/entity/Q35947769

about

CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics The good and evil of complement activation in HIV-1 infection Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1 Current views on the potential for development of a HIV vaccine.Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model Dimeric 2G12 as a potent protection against HIV-1.A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody.Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations.Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection.In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade Monoclonal antibody-based candidate therapeutics against HIV type 1.Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies A summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, 10 March 2006.Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers.4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response.The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design Rational design of membrane proximal external region lipopeptides containing chemical modifications for HIV-1 vaccination.Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked Anti-HIV B Cell lines as candidate vaccine biosensors.Dendritic cells preferentially transfer CXCR4-using human immunodeficiency virus type 1 variants to CD4+ T lymphocytes in trans Monoclonal antibodies for prophylaxis and therapy of infectious diseases.Conservation, Compensation, and Evolution of N-Linked Glycans in the HIV-1 Group M Subtypes and Circulating Recombinant Forms.Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN.Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs

P2860

Q21090521-E3AEBB92-7E50-4CC8-B56C-A69EE6E47455 Q28275986-073A10C0-42B2-44A4-B5C3-AE324054A1AB Q28728527-251C3245-9788-46B2-ACEF-DF479B38CB0F Q30397595-7BC8B3AD-842A-4F77-98BC-7674F7FDD537 Q33417195-D8888DE3-995B-40F3-86F1-A0BD020A7610 Q33518005-5FD4EEBE-7FE3-4E73-B923-9036E1536965 Q33526340-9E41DC08-DEA6-4894-A4E5-B7A7409DDB91 Q33592852-CDFFDCC5-8EC1-4FAC-8D1C-641F5E3B5356 Q33676640-10B8EAF4-CF66-465A-860B-1695809E5900 Q33780961-9533DC5F-1A12-40C3-A5D6-8D4D5F5561FC Q33969383-17CD109F-3B46-4F99-AEBC-BFB537FFE2C9 Q33990484-EE63741C-C10D-4B5B-A7EE-EDDD8C689031 Q34044256-37766937-8F39-494B-8537-F79263A6B66E Q34229664-223E8C47-5395-4CA4-9462-9602166DB1DC Q34309493-9C5E1DFC-3E8C-450E-AAA9-460DC0C7216F Q34536782-578D26E4-2232-48E7-BAF5-838D0EF49724 Q34594036-30F36FF7-13B5-4725-815A-AADF2A8A16AD Q34594726-4ACB71DD-0044-42FF-9721-7B52C1B4802E Q34937404-5D71F469-2F0B-4481-A339-F7B897367A71 Q35012462-B30B04C3-83FD-49F9-B977-0A0D427837E2 Q35076953-AB5E0B89-D2B5-43F5-A8E2-7D42B4040AF4 Q35689608-96C411DF-2853-4AAA-9B2B-2B193243E7F4 Q35874415-7AAC010E-A5F5-4755-810E-06598559ADBD Q35904501-CAA3CCC4-2DBB-4A72-9086-B02BF78FABE2 Q35973601-D47C3EC7-4766-4F44-BEF9-738079AD6A3C Q36099045-503C10C5-ED3D-475A-AEA7-282561BEC4B2 Q36105672-5CDD8706-4801-4973-812D-14D53DD1B8EB Q36247783-86BD729B-7AFE-4355-937C-C9F175F137DE Q36298503-CE73BC03-28B7-4DCA-8D9E-29BC1A759D91 Q36424125-4022C82C-602A-44C0-BE51-BD80EE2F23E1 Q36483956-D127E5CD-4029-471C-8203-D87F0F414E88 Q36497712-01C8C712-1576-4F05-83D1-D27664E8EB57 Q36504833-E5F3D96A-6870-4158-9266-BE7506BA58FD Q36540060-80936074-39B4-4237-A35C-DE8203B783C3 Q36766704-C26F73F6-E065-44E4-9A5F-86AC83498F0F Q36845632-D7AFBC1C-0A39-4EFE-B043-A908BCC54448 Q36989900-0CA2757A-F72B-45F4-843B-B9ECF983D586 Q37153097-EAA72B49-4EE7-4BA9-A38C-5C5DD5C4ACC8 Q37208595-6562CB33-BEBE-4368-B1BB-5CEEF1195F4F Q37233074-D90DAEC7-2034-494A-9A2E-F14F82F8DC77

P2860

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

http://www.wikidata.org/entity/Q35947769

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

@ast

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

@en

type

label

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

@ast

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

@en

prefLabel

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

@ast

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

@en

P1433

Q35947769-A658B0A9-1EF5-4C31-9E7E-15DCF3717CB7

P1476

Q35947769-5FC4BDA5-5A22-4621-8052-01B76FF1DDFF

P2093

Q35947769-0D9DC5A8-9606-4DDD-8AA4-01CAE55A2480

Q35947769-1E96572E-6D90-4D44-9B94-E58122E0BF15

Q35947769-4BFBA442-A82E-41C4-9ACF-68C8B587CEFE

Q35947769-4C1A698F-04DB-4712-8DEE-16F3EDD0CDBF

Q35947769-5BEBF104-433F-48DB-B92E-C9F4F2EE7966

Q35947769-8065CE38-B31E-4F39-93B6-0592055D61BE

Q35947769-C80D6C6C-5658-42FD-9217-29EB8B775387

Q35947769-C8F95C2B-60D2-485E-80EE-1E50E7AFE63B

Q35947769-DFECE972-7F30-4EDE-81BB-775EEECD9C17

P2860

Q35947769-023B7EEE-8B70-461B-A449-1A886C60F4C8

Q35947769-0525201D-C25F-4E7A-95F4-6AADB334327B

Q35947769-0C1901CA-302E-496D-97EC-21726380109A

Q35947769-10A5674B-A83A-40D8-A7B2-BE3B98340A7D

Q35947769-15D6A70D-426E-45A1-A865-65C1D1D0755A

Q35947769-19A5F3FF-1CE9-4B86-AB4F-F009C5E772A5

Q35947769-22274858-699F-40FF-826C-37A049343279

Q35947769-2A252F30-6FA4-4C55-8229-CAF61E767EBE

Q35947769-2CAE5F74-8B5D-4B90-8C7A-0CE3C7FD192B

Q35947769-2E36DC42-BC06-46BD-9B80-BA8CD5EF8BDF

P304

Q35947769-0E6CA521-E028-4952-81D4-0A239AD836BA

P31

Q35947769-07AD446B-E0F3-48FE-A6C6-25A20C17EC75

P356

Q35947769-59B81864-E35F-46FB-BCF6-9C35B3BADC09

P407

Q35947769-B1551A5D-DC6B-461D-BD85-D17FB59F7D96

P433

Q35947769-8B52A31F-6317-4B46-BD7F-BF65175F8DDD

P478

Q35947769-F1582336-D586-458E-AD5C-B1F10368B456

P50

Q35947769-2DF0C0A4-02BC-4C37-9494-1F0FF84EF022

Q35947769-49D07637-E0A7-426D-82C0-9D459BD3375B

Q35947769-60AE8F60-3093-4EEE-9989-3B8BB9F4FEAF

P577

Q35947769-42D8D134-3387-4D4D-A9DB-E4AFDB090FCC

P698

Q35947769-E69A8692-67B6-406C-A43F-9B17B7746332

P921

Q35947769-36951C49-6BEE-482A-9C3F-9A9C2C6EF07B

P932

Q35947769-04DB74EE-BDAA-4E02-A0B7-DE18C2D37029

P356

P1433

Journal of Virology

P1476

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

@en

P2093

Amapola Manrique

http://www.w3.org/2001/XMLSchema#string

Barbara Niederöst

http://www.w3.org/2001/XMLSchema#string

Beda Joos

http://www.w3.org/2001/XMLSchema#string

Christine Leemann

http://www.w3.org/2001/XMLSchema#string

Gabriela Stiegler

http://www.w3.org/2001/XMLSchema#string

Hermann Katinger

http://www.w3.org/2001/XMLSchema#string

Marek Fischer

http://www.w3.org/2001/XMLSchema#string

Peter Rusert

http://www.w3.org/2001/XMLSchema#string

Rainer Weber

http://www.w3.org/2001/XMLSchema#string

P2860

Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

Antibody vs. HIV in a clash of evolutionary titans

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates

The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles

Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

The antigenic structure of the HIV gp120 envelope glycoprotein

Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection

P304

8793-8808

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.00598-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P50

Alexandra Trkola

Huldrych F Günthard

P577

2007-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17567707

http://www.w3.org/2001/XMLSchema#string

P921

P932

1951363

http://www.w3.org/2001/XMLSchema#string